TY  - JOUR
TI  - Biosimilars
AB  - For a drug to be defined as a biosimilar, it should be fairly similar to the previously approved original or reference product. The minor variances 
in its inactive ingredients should not pose clinically significant differences from the reference product in terms of safety and efficacy potency. 
Biosimilars of infliximab and adalimumab have received reimbursements in our country. By lowering treatment costs, biosimilars may provide 
considerable economies for health systems that reimburse healthcare expenditures.
AU  - BÜLBÜL BASKAN, EMEL
DO  - 10.4274/turkderm.galenos.2022.06978
PY  - 2022
JO  - Türkderm Türk deri hastalıkları ve frengi arşivi
VL  - 56
IS  - 1
SN  - 2717-6398
SP  - 75
EP  - 76
DB  - TRDizin
UR  - http://search/yayin/detay/534091
ER  -